Vol.

No.

February 04, 2022Feb 04, 2022

DOWNLOAD THE PDF

FDA says it had no input as companies developed checkpoint inhibitors in China

Cover Story

Conversation with The Cancer Letter Regulatory News

FDA says it had no input as companies developed checkpoint inhibitors in China

By Paul Goldberg

FDA is preparing to review an estimated 25 applications for cancer drugs that are being developed based largely—and in many cases entirely—on data from mainland China.

White House

Biden reignites Cancer Moonshot, convenes “Cancer Cabinet” to increase screening and halve cancer deaths before 2050

By Alice Tracey and Matthew Bin Han Ong

Guest Editorial

Congressional inaction harms federally funded oncology research and our patients:
The time for the cancer community to act is now

By Howard A. "Skip" Burris III, Charles D. Blanke, Monica M. Bertagnolli, Peter J. O'Dwyer, Mitchell D. Schnall, Douglas S. Hawkins, Quynh-Thu Le, Robert S. Mannel, Norman Wolmark and Janet Dancey

Black History Month Cancer History Project Conversation with The Cancer Letter Free

Wayne Frederick on the legacy of LaSalle Leffall, Jr.

By Robert A. Winn

Free In the Archives

Black History Month: Highlights from 2021

Clinical Trials & Tribulations

Leveraging cutting-edge technology to address the impact of COVID-19 on cancer screening, diagnosis, and treatment

By Gustaf Salford

In Brief

Mignon Loh, Elizabeth Swisher named deputy directors at Fred Hutch/UW Cancer Consortium

UChicago to build $633M cancer center on South Side

City of Hope completes acquisition of CTCA

ASCO, ACS collaborate to increase online access to cancer information

IARC launches World Code Against Cancer Framework

MSK announces $100M gift to create Marie-Josée and Henry R. Kravis Cancer Ecosystems Project

Noe Crespo named co-leader of cancer control at Moores Cancer Center UCSD

Iberia Romina Sosa named chief of the Division of Hematology at Fox Chase

Wells Messersmith named CMO of oncology services at UCHealth

Margaret von Mehren named vice chair of Department of Hematology/Oncology at Fox Chase

Sanjay Goel named director of Rutgers Phase I/Investigational Therapeutics Program

Mateusz Opyrchal named inaugural Vera Bradley Foundation Scholar in Breast Cancer Discovery at IU

Linda Fleisher receives Academy of Oncology Nurse & Patient Navigators Lifetime Achievement Award

Clinical Roundup

President’s Cancer Panel calls for improved equity and access as cancer screening rates lag

UAB study supports virotherapy as a potential treatment for glioblastoma

Yale study explores treatment for advanced triple-negative breast cancer

Drugs & Targets

FDA investigating possible increased risk of death with lymphoma drug Ukoniq

Veru, Eli Lilly to evaluate enobosarm + Verzenio in phase III ENABLAR-2 trial

NCI Trials

NCI Trials for February 2022

The National Cancer Institute approved the following clinical research study last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 35 - September 25, 2026